Sandoz’s Tyruko biosimilar granted FDA approval to treat relapsing MS
The disease-modifying therapy is approved to treat all indications covered by Tysabri
Read More
Tag: MS
NICE opts to reject Acorda’s MS drug Fampyra
The MS Society responds as MS therapy Fampyra is rejected
Read More
Novartis presents positive new data on relapsing MS treatment
Data has shown that treatment with Kesimpta is associated with fewer relapses and reduced risk of worsening disability
Read More
Novartis’ Kesimpta trial provides positive results for MS patients
MS patients given boost by results of study into Kesimpta – a self-administered treatment with potential to improve lives
Read More
UK launch for progressive multiple sclerosis mega-trial
It is hoped that the multi-armed Octopus trial will rapidly speed up development of new treatments
Read More
EU nod for new formulation of Biogen’s Tysabri
A subcutaneous formulation will now be available to treat relapsing-remitting multiple sclerosis
Read More
Novartis bags EU, UK licences for MS therapy Kesimpta
Kesimpta is the first self-administered B-cell therapy for patients with relapsing forms of multiple sclerosis
Read More
Novartis’ melanoma combo fails in PhIII
The study assessed investigational immunotherapy spartalizumab (PDR001) in combination with targeted therapies Tafinlar and Mekinist
Read More
NICE rejects Novartis’ Mayzent for secondary progressive MS
NICE says the cost-effectiveness of the drug is uncertain, but Novartis says the decision denies patients access to the first licensed oral therapy for SPMS with active disease
Read More
Biogen launches digital self-help tool to support mental health in MS
ACT MySelf, was developed by Biogen in collaboration with people living with MS, the MS Trust, a team of MS specialist nurses and an MS clinical psychologist
Read More
Charity launches online support services for self-isolators with MS
Calls to the MS helpline have increased significantly
Read More
Novartis highlights benefits of Mayzent in MS
The data underscore the advantages of early treatment initiation, the firm notes
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
